Mildenberger H
Kinderchirurgische Klinik, Med. Hochschule, Hannover.
Langenbecks Arch Chir. 1988;Suppl 2:511-4.
Survival rates in patients with neuroblastoma did not significantly improve during the last two decades. This is particularly true for stage IV tumors. This stage seems to be a tumor fundamentally different from the more localized stages in its biological behavior, and it is not known, whether stage IV tumors originate from a localized stage by metastatic spread. Intensive investigations regarding new therapeutic approaches on an immunological basis or by stimulation of tumor maturation have been unsuccessful by now. Surgery in neuroblastoma has to be adapted to the particular stage to be treated. Certainly, surgery has to be incorporated into a therapeutic strategy which includes the whole spectrum of modern anticancer therapy. Such a therapeutic strategy will be provided by multicenter cooperative studies, such as the neuroblastoma study designed by the German Association of Paediatric Oncology (GPO). A treatment of neuroblastoma without incorporation in a multicenter cooperative study should not be accepted as modern standard.
在过去二十年中,神经母细胞瘤患者的生存率并未显著提高。对于IV期肿瘤来说尤其如此。这个阶段的肿瘤在生物学行为上似乎与更局限的阶段有着根本的不同,并且尚不清楚IV期肿瘤是否通过转移扩散起源于某个局限阶段。到目前为止,关于基于免疫或刺激肿瘤成熟的新治疗方法的深入研究均未成功。神经母细胞瘤的手术必须根据要治疗的特定阶段进行调整。当然,手术必须纳入包括整个现代抗癌治疗范围的治疗策略中。这样的治疗策略将由多中心合作研究提供,例如德国儿科肿瘤协会(GPO)设计的神经母细胞瘤研究。不纳入多中心合作研究的神经母细胞瘤治疗不应被视为现代标准治疗。